Individualized immunotherapy based on blood cell chimerism after allogeneic hematopoietic stem cell transplantation

WAN Li-ping,WANG Chun,JIANG Ying,YAN Shi-ke,JIANG Jie-ling,YANG Jun,CAI Yu,WANG Xiao-rui

DOI: https://doi.org/10.16150/j.1671-2870.2010.01.008

2010-01-01

Abstract:Objective To investigate the relationship between blood cell chimerism and relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT),and to evaluate the efficacy of individualized immunosuppressant therapy and donor lymphocyte infusion based on the changes of blood cell chimerism.Methods T lymphocyte,B lymphocyte and NK cell chimerism were determined by PCR amplification of short tandem repeat sequences in 106 successfully engrafted patients with allo-HSCT.Individualized immunosuppressant therapy and donor lymphocyte infusion were administrated to patients based on the change of blood cell chimerism.Results T lymphocytes of 6 patients achieved full donor chimerism from mixed chimerism with the reduction of immunosuppressant dose.T lymphocytes of 12 patients achieved full donor chimerism from decrease of T cell chimerism rate after reduction of immunosuppressant dose.Of the 24 patients relapsed,6 patients had 10 times of reduction in blood cell chimerism rate,and achieved full donor chimerism temporarily after reduction of immunosuppressant dose,but all were finally relapsed.Donor lymphocyte infusion were also given 23 times to 12 patients when the disease was relapsed or progressed,8 of them also received chemotherapy pre-or post-donor lymphocyte infusion.Five of these patients achieved complete remission again,and the others died of relapse.The incidences of grade Ⅱ-Ⅳ acute GVHD was 28.3%,chronic GVHD was 55.7%.Sixty-five patients survived free of diseases and 41 patients died after a median follow up of 17 months.Expected 3-year survival rate of standard risk patients was 59.0%,high risk patients was 44.7%.Conclusions T,B and NK lymphocyte chimerism could be used as a relapse predictor of hematological malignancy.Individualized immunotherapy based on changes of blood cell chimerism could delay or avoid clinical relapse,and did not increase the incidence of acute GVHD.